Treatment of Severe Hemophilia A with Factor VIII Inhibitors
This protocol covers the management of severe hemophilia A — defined by factor VIII activity below 1 IU/dL — in patients who have developed factor VIII inhibitors at a titer above 0.6 Bethesda units. The presence of inhibitors fundamentally changes the clinical approach to bleeding prevention.
Clinical Scenario
Severe hemophilia A (factor VIII activity <1 IU/dL) with factor VIII inhibitors at a titer >0.6 Bethesda units (BU). This combination defines a high-complexity subgroup requiring a distinct management strategy from non-inhibitor severe hemophilia A.
Treatment Approach
ISTH guidelines recommend prophylaxis over episodic treatment for this population. The regimen for this scenario involves a subcutaneously administered agent with flexible dosing schedules designed to reduce treatment burden — the full protocol including agent selection, scheduling options, and clinical decision points is available below.
References
In individuals with severe hemophilia A with inhibitors, the ISTH Hemophilia Guideline Panel suggests prophylaxis over episodic treatment of bleeding events (conditional recommendation, based on low-certainty evidence ⨁⨁◯◯).
A positive inhibitor is defined as a titer of >0.6 Bethesda units (BU) for FVIII and ≥0.3 BU for FIX.
In individuals with severe hemophilia A with inhibitors, the ISTH Hemophilia Guideline Panel suggests prophylaxis with emicizumab over bypassing agents (conditional recommendation, based on very low–certainty evidence ⨁◯◯◯).
Emicizumab may offer a lower treatment burden for patients given its weekly, biweekly, or every 4-week schedule and subcutaneous administration.
DOI: 10.1016/j.jtha.2024.05.026
View source ↗